Detalhe da pesquisa
1.
Estimating Post-treatment Recurrence After Multidrug-Resistant Tuberculosis Treatment Among Patients With and Without Human Immunodeficiency Virus: The Impact of Assumptions About Death and Missing Follow-up.
Clin Infect Dis
; 78(1): 164-171, 2024 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37773767
2.
Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed Drugs.
Clin Infect Dis
; 78(1): 144-148, 2024 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37606512
3.
Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis.
Am J Respir Crit Care Med
; 207(11): 1525-1532, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36802336
4.
Low detection rate of RT-PCR-confirmed COVID-19 using IgM/IgG rapid antibody tests in a large community sample in Lima, Peru.
BMC Infect Dis
; 23(1): 62, 2023 Feb 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36732690
5.
Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies Among Market and City Bus Depot Workers in Lima, Peru.
Clin Infect Dis
; 74(2): 343-346, 2022 01 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-33881476
6.
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort.
Clin Infect Dis
; 75(6): 1006-1013, 2022 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-35028659
7.
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
Clin Infect Dis
; 75(8): 1307-1314, 2022 10 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35243494
8.
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings.
Eur Respir J
; 59(1)2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34140298
9.
Prevention and management of hearing loss in patients receiving ototoxic medications.
Bull World Health Organ
; 100(12): 789-796A, 2022 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36466201
10.
Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study.
Am J Respir Crit Care Med
; 203(1): 111-119, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32706644
11.
Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis.
Clin Infect Dis
; 71(2): 415-418, 2020 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31676905
12.
Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis.
Emerg Infect Dis
; 26(3)2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31922953
13.
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.
Am J Respir Crit Care Med
; 200(10): e93-e142, 2019 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31729908
14.
Nepali Linguistic Validation of the Velopharyngeal Insufficiency Effects on Life Outcomes Instrument: VELO-Nepali.
Cleft Palate Craniofac J
; 57(8): 967-974, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32054301
15.
Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.
PLoS Med
; 16(3): e1002767, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30901331
16.
The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
BMC Infect Dis
; 19(1): 733, 2019 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31429722
17.
Ascertainment Bias in TB Treatment Trials: Can Systematic Assessment of Objective Endpoints Solve It?
Am J Respir Crit Care Med
; 207(10): 1269-1270, 2023 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36952239
18.
Efficacy and Safety of High-Dose Rifampin in Pulmonary Tuberculosis. A Randomized Controlled Trial.
Am J Respir Crit Care Med
; 198(5): 657-666, 2018 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29954183
19.
Asthma and atopy prevalence are not reduced among former tuberculosis patients compared with controls in Lima, Peru.
BMC Pulm Med
; 19(1): 40, 2019 Feb 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-30760258
20.
Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis.
Antimicrob Agents Chemother
; 62(10)2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30012767